Oncotherapy Solutions, LLC
  
                         

Home

Focusing on scientific discovery and innovation in targeted therapy and immuno-oncology to save human lives: 

Cancer is the second most common cause of death in the US, exceeded only by heart disease.
 One of every four deaths in the United States is due to cancer.  The American Cancer Society estimates that in 2014, about 1,665,540 Americans were diagnosed with invasive cancer, and 585,720 Americans died of this disease.  Currently used cancer drugs such as chemotherapeutic agents and monoclonal antibodies have limitations due to their toxicities and are ineffective against tumors with drug resistance.  Thus, there is an urgent need for more potent, targeted and safer cancer therapeutics.  Oncotherapy Solutions, a new biotechnology company is utilizing its previous expertise in preclinical drug development and delivery to design and test new pipeline of targeted, potent, stable and safer drug conjugates, kinase inhibitors and vaccines for the treatment of prostate, ovarian, breast, colon, pancreatic and lung cancers. 


The company currently has two preclinical programs:


The first program is focused on the development of novel, potent and safer drug conjugates carrying new chemotherapeutic agents.  We have completed proof of concept in-vitro preclinical studies of these drug conjugates on triple-negative breast cancer (TNBC), castration-resistant prostate cancer (CRPC) and drug-resistant ovarian cancer.  We have also completed the efficacy
 in-vivo studies of our novel lead drug conjugate using MDA-MB-231 orthotopic triple-negative breast cancer mouse model.  The lead drug conjugate showed a dramatic and highly significant tumor growth inhibition in-vivo with no change in animal weight. The majority of treated mice had no detectable tumors (complete response) after 3 weekly injections of 1.6 mg/kg of our lead drug conjugate and we are currently conducting toxicology studies.  Further efficacy and toxicology studies on immuno-deficient mice bearing orthotopic human MDA-MB-231 triple-negative breast cancer showed that our drug conjugate is also effective with excellent safety profile at 2 weekly injections of 450 µg/kg.  In addition to the direct anti-tumor activity we are planning to investigate a potential immuno-stimulatory activity of our drug conjugates alone or in combination with immune checkpoint inhibitors in humanized NSG-SGM3 mice engrafted with human CD34+ hematopoietic stem cells and bearing MDA-MB-231 or BR1126 patient-derived triple-negative breast cancers.  Our drug conjugate is highly targeted to cancer cells and safer than standard chemotherapy which suffers from high toxicity and low potency in drug-resistant cancers.  Our lead drug conjugate is also expected to be potent against other solid tumors including pancreatic and colon cancers. 

 
The second program is focused on the development of new immunotherapy small molecule
 drugs and vaccines that will help patient's own immune system, namely cytotoxic T cells and natural killer cells to seek and destroy cancer cells that express specific antigens at their surface. Our future plan is to screen well-designed small molecule drugs and vaccine  candidates for the treatment of TNBC and CRPC as well as drug-resistant ovarian, pancreatic and colon cancers. 
Website Builder